INVX shareholder plans sale of 10,000 common shares

A shareholder of INVX, identified as Mark Reddout, has filed to sell up to 10,000 shares of common stock through UBS Financial Services, Inc. on the NYSE, with an approximate aggregate market value of $300,000.00.

Rhea-AI Filing Summary

A shareholder of INVX, identified as Mark Reddout, has filed to sell up to 10,000 shares of common stock through UBS Financial Services, Inc. on the NYSE, with an approximate aggregate market value of $300,000.00. The filing also lists prior sales of 10,750 common shares for about $301,000.00 on June 2, 2026, and notes that the 10,000 shares to be sold were received as a stock award from the issuer on July 3, 2024.

Key Figures

Shares to be sold: 10,000 shares Proposed aggregate market value: $300,000.00 Exchange: NYSE +4 more

7 metrics

Shares to be sold 10,000 shares Common stock proposed for sale under Form 144

Proposed aggregate market value $300,000.00 Value of 10,000 common shares to be sold

Exchange NYSE Planned market for sale of common shares

Shares sold in past 3 months 10,750 shares Common shares sold on 06/02/2026

Aggregate value of past sale $301,000.00 Value of 10,750 shares sold on 06/02/2026

Stock award date 07/03/2024 Date the 10,000 shares to be sold were awarded

Form 144 sale end date 08/04/2026 Date associated with the proposed sale period

Key Terms

Form 144, Stock Award, Securities Sold During The Past 3 Months, aggregate market value

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Stock Award financial

"Common | 07/03/2024 | Stock Award | Issuer"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

aggregate market value financial

"10000 | 300000.00 | 68759676 | 08/04/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the INVX Form 144 filing disclose?

The filing discloses that Mark Reddout plans to sell up to 10,000 INVX common shares via UBS Financial Services on the NYSE, with an estimated aggregate value of $300,000.00, and that these shares came from a prior stock award.

How many INVX shares are proposed to be sold under this Form 144?

The shareholder proposes to sell up to 10,000 shares of INVX common stock. The filing lists an approximate aggregate market value of $300,000.00 for this planned sale through UBS Financial Services on the NYSE.

What prior INVX share sales are reported in this Form 144?

The filing reports prior sales of 10,750 INVX common shares on June 2, 2026 for an approximate aggregate value of $301,000.00. These are shown under “Securities Sold During The Past 3 Months.”

How were the INVX shares to be sold originally acquired?

The 10,000 INVX shares to be sold were acquired as a Stock Award from the issuer dated July 3, 2024. The filing identifies the acquisition form as “Stock Award” and the acquisition party as the issuer.

Which broker is handling the proposed INVX share sale?

The proposed sale of 10,000 INVX common shares is to be handled by UBS Financial Services, Inc., based at 11 Madison Ave, 4th Floor, New York, NY 10010, with trading indicated for the NYSE market.

What is the approximate market value of securities reported in the INVX Form 144?

The proposed sale has an approximate aggregate market value of $300,000.00 for 10,000 shares, and the past 3‑month sale noted in the filing totals about $301,000.00 for 10,750 shares of INVX common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 04:10 PM Accepted by SEC EDGAR 08/04/2026 - 04:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002025761
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Innovex International, Inc.
SEC File Number	001-13439
Address of Issuer	19120 KENSWICK DRIVE HUMBLE TEXAS 77338
Phone	3463980000
Name of Person for Whose Account the Securities are To Be Sold	Reddout Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	10000	300000.00	68759676	08/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/03/2024	Stock Award	Issuer			10000	07/03/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Reddout 19120 KENSWICK DRIVE Humble TX 77338	Common	06/02/2026	10750	301000.00

144: Remarks and Signature

Remarks
Date of Notice	08/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Mark Reddout
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)